This 2017 review evaluates the safety profile of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), in postoperative pain management. Ketorolac is effective in reducing pain and opioid consumption; however, concerns exist regarding its impact on bone healing, renal function, and bleeding risk. Evidence indicates that standard doses do not impair bone
This 2003 study assessed the impact of weight loss on renal function in eight severely obese individuals (mean BMI 48.0 ± 2.4) without overt kidney disease. Compared to lean controls, obese participants exhibited elevated glomerular filtration rate (GFR) and renal plasma flow (RPF), indicating glomerular hyperfiltration. Following a 32% reduction
This review explores the impact of heavy metal exposure, particularly cadmium and lead, on chronic kidney disease (CKD) and cardiovascular disease (CVD). It highlights that both acute and chronic low-level exposures contribute to renal and cardiovascular toxicity. The article discusses the potential benefits of chelation therapy, specifically with calcium EDTA,
This 2015 review examines calcitonin, a 32-amino acid hormone secreted by thyroid C-cells, focusing on its physiological role and clinical relevance. Calcitonin is stimulated by elevated serum calcium and gastrointestinal hormones like gastrin, contributing to the prevention of hypercalcemia. It also stimulates renal production of 1,25-dihydroxyvitamin D at a site
This article discusses the phenomenon where methylene blue, a diagnostic dye, was not visualized in the urine of two patients with clinically normal renal function after intravenous injection. This lack of visualization is due to methylene blue’s metabolism into a colorless compound called leukomethylene blue, which cannot be detected in
The study titled “α-lipoic acid in patients with autosomal dominant polycystic kidney disease” (Nutrition, 2020, PMID: 31790890) investigated the effects of α-lipoic acid (ALA) supplementation on systemic inflammation, endothelial dysfunction, and atherosclerosis in patients with autosomal dominant polycystic kidney disease (ADPKD). In a six-month intervention, 33 patients received 1.6 g
